EU approves Sanofi drug for chronic lung disease
The Peninsula
Paris: The European Union has approved Sanofi s blockbuster drug Dupixent for the treatment of chronic obstructive pulmonary disease (COPD), the Frenc...
Paris: The European Union has approved Sanofi's blockbuster drug Dupixent for the treatment of chronic obstructive pulmonary disease (COPD), the French pharmaceutical giant said on Wednesday.
The debilitating disease, sometimes called "smoker's lungs", is the third-leading cause of death worldwide, according to the World Health Organization.
"Dupixent is the first new treatment approach for COPD in more than a decade and a new option for approximately 220,000 adults in the EU," Sanofi said in a statement.
The EU's European Medicines Agency "is the first regulatory authority in the world to approve Dupixent for COPD patients," it added.
The drug, which has now been approved for six different illnesses in the EU, is also being reviewed by the United States, Japan and China for COPD patients.